AI CuratorAI-generated

Research summary · 10 d ago

AI summary · not yet reviewedSubjects not reportedObservationalPublished in a peer-reviewed journal

Predictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis

In a study with 866 patients with relapsing-remitting multiple sclerosis (RRMS), 10.5% had a relapse in the first year after switching to ofatumumab (OFA). Factors like higher disability scores and recent relapses prior to switching were associated with an increased risk of relapse, especially for those switching from fingolimod, as longer washout periods heightened this risk.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42874502)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not yet assessed
Mechanism: Not yet assessed
Evidence strength: Not yet assessed
Outcome: Not yet assessed

Why it matters

These findings help understand factors influencing relapse after switching to OFA, which could inform monitoring strategies during treatment transitions in RRMS.

What this does not prove

The study does not establish causation between washout duration and relapse risk, making it unclear if longer washouts directly result in higher relapses.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Observational
Participants / samples: 866 · basis not reported
Randomised: No
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-10-10
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidencePredictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis. ↗DOI: 10.1016/j.msard.2026.107981

Supporting passages (9)

study designOBJECTIVES: To evaluate predictors of first-year relapse after switching from selected pDMTs to OFA in adults with RRMS enrolled in the MSBase Registry.

sample sizeAmong 866 patients (median EDSS 2.5), 10.5% experienced a relapse in the first year on OFA.

randomizedWashout period duration was not associated with relapse in the overall cohort, but longer washout among fingolimod switchers increased relapse risk (HR 1.34, 95% CI 1.01-1.79, p = 0.044).

peer reviewedThese findings support tailored monitoring and further research to optimise treatment transitions in RRMS.

interventionINTRODUCTION: Ofatumumab (OFA) is an emerging therapy for relapsing-remitting multiple sclerosis (RRMS), but the impact of prior disease-modifying therapy (pDMT) on outcomes after switching is unclear.

primary endpointOBJECTIVES: To evaluate predictors of first-year relapse after switching from selected pDMTs to OFA in adults with RRMS enrolled in the MSBase Registry.

findingsCONCLUSION: Relapse after switching to OFA is influenced by baseline disability, recent relapse, and prior fingolimod use.

publication datePublication date: 2026-10-10

limitationsTitle: Predictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.